MOTS-c is a 16-amino-acid mitochondrial-derived peptide, encoded by a short open reading frame inside the mitochondrial 12S rRNA gene (MT-RNR1). It was identified by researchers at USC in 2015 and is studied as a regulator of metabolism, insulin sensitivity, and the cellular energy sensor AMPK. It is sold as a research chemical, not an approved medicine.

What Is MOTS-c? The Mitochondrial Peptide Explained

MOTS-c is one of the more unusual peptides people ask about: your own body makes it, and it is encoded not in your regular DNA but inside your mitochondria. Here is what it actually is, what the research does and does not show, the exercise finding almost everyone gets backwards, and where it stands with regulators in 2026.

WeightSnap Research · reference, not medical advice · last reviewed July 2026

Read this first. MOTS-c is sold as a research chemical and is not an approved medicine. Most of the effects below come from cell and animal studies, not human trials, so they describe what researchers are investigating, not proven effects in people. This page is reference material, not medical advice, not a recommendation to use anything, and not a dosing protocol.

What MOTS-c is

MOTS-c stands for Mitochondrial ORF of the 12S rRNA type-c. It is a 16-amino-acid peptide, and the interesting part is where it comes from: it is encoded by a short open reading frame tucked inside the mitochondrial 12S rRNA gene (MT-RNR1), not in the DNA in your cell nucleus. That makes it one of a small family of mitochondrial-derived peptides, molecules the mitochondria produce that then act as signals to the rest of the cell.

It was identified in 2015 by a research group at USC (Changhan Lee, Pinchas Cohen, and colleagues) and published in Cell Metabolism. Since then it has become one of the more heavily studied mitochondrial-derived peptides, largely because of its links to metabolism and aging. The short version of its job: it appears to act as a retrograde signal, a message sent from the mitochondria back to the nucleus, that helps the cell adjust its metabolism under stress.

What the research examines (and the big caveat)

MOTS-c has a real and growing research literature, but framed accurately these are areas of investigation, mostly in cells and rodents, not established human benefits:

The AMPK energy pathway. MOTS-c activates AMPK, the cell's main low-energy sensor, partly by interfering with the folate one-carbon cycle. AMPK is the same pathway the diabetes drug metformin nudges, which is a large part of why MOTS-c drew metabolic interest.
Insulin sensitivity and glucose uptake. In lab models it promotes glucose uptake into muscle in a way that does not fully depend on insulin, which is why it is studied in the context of insulin resistance.
Obesity and insulin resistance. The original 2015 work reported that MOTS-c reduced diet-induced obesity and insulin resistance in mice.
Aging and physical decline. Later work framed MOTS-c as an exercise-linked regulator of age-related physical decline, with effects on muscle function in older animals.

The caveat that matters most: the great majority of this is cell and rodent research. Efficacy has not been confirmed in human clinical trials of the peptide itself, and there is no completed human efficacy trial. Promising animal metabolic data is not the same as a proven, safe human treatment, and anyone selling MOTS-c as a settled fat-loss or anti-aging drug is well ahead of the evidence.

The exercise finding people get backwards

This is the part worth slowing down on, because the popular story and the strongest evidence point in nearly opposite directions.

The most robust human finding is not that injecting MOTS-c makes you fitter. It is that exercise raises your own MOTS-c. In a 2021 Nature Communications study, a single bout of exercise drove roughly a 12-fold rise in MOTS-c in the skeletal muscle of young men, along with about a 1.6-fold rise in the amount circulating in the blood. In other words, MOTS-c looks like something your body releases because you worked out, a marker and mediator of the exercise response.

The reputation as an injectable "exercise in a vial" comes mostly from animal studies. In mice, MOTS-c treatment improved treadmill performance, and the effect was striking in old animals: treated aged mice ran roughly 2-fold longer and about 2.16-fold farther than untreated controls, and some reached running stages that no untreated old mouse managed. Impressive, but it is a mouse on a treadmill, not a human outcome.

The honest summary: in humans, the clear result is that exercise induces MOTS-c. The idea that supplementing MOTS-c reproduces the benefits of exercise in people is a hypothesis drawn from animal data, not a demonstrated human effect. It is a genuinely interesting molecule at an early stage, and it is easy to oversell.

Regulatory status in 2026

This picture is moving, so it is dated on purpose. As of mid-2026:

MOTS-c is not FDA-approved for any indication and has not completed human efficacy trials.
It was removed from the FDA's 503A Category 2 list (the compounding "significant safety risk" bucket) in early 2026, and it is scheduled for a Pharmacy Compounding Advisory Committee (PCAC) review on July 23-24, 2026, which will weigh it for the 503A bulk substances list. That is the same review cycle several other research peptides are going through.
It is sold Research Use Only. The "for research purposes only" label on a vial is a marketing disclaimer, not a guarantee of legality, purity, or safety.
The only completed human trial to date used CB4211, a synthetic MOTS-c analogue developed by CohBar, which passed early Phase 1b safety testing. There is no active Phase 2 or Phase 3 programme for native MOTS-c itself.

Because the compounding rules are being decided through 2026, treat any seller's claim that MOTS-c is "now approved" or "fully legal" with caution, and check the current FDA position directly rather than trusting a page like this one to stay current.

A note for athletes

MOTS-c is on the World Anti-Doping Agency prohibited list, banned at all times under Section S4.4 (metabolic modulators), as an AMPK activator. Because it has no approved medical use, there is no therapeutic use exemption available. For any drug-tested athlete, that makes it disqualifying, and worth flagging clearly.

How MOTS-c is dosed

There is no established human dose, for the simple reason that native MOTS-c has not been through human clinical trials. Amounts passed around in the research community are anecdotal, they vary widely, and they are not a medical standard. A specific dose is a decision for a licensed provider, not something a reference page should hand out. That is the describe-not-prescribe line, and this page stays on the right side of it.

It is also worth being honest that the safety profile in humans is not well characterised. Because there are no completed efficacy trials, reported effects lean on anecdote and early data. Anti-doping and community sources have noted things like injection-site irritation, a raised heart rate, insomnia, and fever, with long-term effects simply unknown. None of that is a reason to treat it casually.

What a reference page can safely help with is the arithmetic. If you are reconstituting a vial and need to convert milligrams, bacteriostatic water, and syringe units, that is pure math: the free reconstitution calculator handles it without recommending a dose.

A note from us

Full transparency: WeightSnap's founder is personally running a MOTS-c protocol alongside a retatrutide maintenance dose, which is part of why this reference exists. That first-hand experience is documented separately, in his own words, on the blog rather than here, so this page can stay a neutral technical reference. If you want the personal side, why he started it, what the injection feels like, and an honest week-one read with a full maybe-placebo caveat, follow along on the blog. WeightSnap the app logs every peptide injection alongside vial supply, which is how that experiment is being tracked.

Frequently asked questions

What is MOTS-c?

A 16-amino-acid mitochondrial-derived peptide, encoded by a short open reading frame inside the mitochondrial 12S rRNA gene (MT-RNR1). Identified by researchers at USC in 2015, and studied as a regulator of metabolism, insulin sensitivity, and the energy sensor AMPK. Sold as a research chemical, not an approved medicine.

What is MOTS-c studied for?

In mostly preclinical (cell and rodent) research, it has been examined for metabolic homeostasis, insulin sensitivity and glucose uptake, obesity and insulin resistance, and age-related physical decline. These are research findings, not confirmed human benefits.

Does MOTS-c improve exercise performance?

The honest picture is nuanced. The strongest human finding is that exercise raises your own MOTS-c (one study measured roughly a 12-fold rise in skeletal muscle after acute exercise), rather than proving that injecting it makes people fitter. The performance gains (mice running longer and farther) come from animal studies. It is active research, not a settled human performance aid.

Is MOTS-c FDA approved?

No. As of mid-2026 it is not approved and has no completed human efficacy trials. It was removed from the FDA 503A Category 2 list in early 2026 and is scheduled for a Pharmacy Compounding Advisory Committee review on July 23-24, 2026. Sold research-use-only. Its status is changing, so verify the current FDA position.

Is MOTS-c banned in sport?

Yes. WADA prohibits it under Section S4.4 (metabolic modulators) as an AMPK activator, at all times, with no therapeutic use exemption because it has no approved medical use. Disqualifying for tested athletes. Not legal advice.

How is MOTS-c dosed?

There is no established human dose (no completed human trials of the native peptide). Community amounts are anecdotal and not a medical standard, and dosing is a provider decision, not something this page specifies. For reconstitution arithmetic only, use the reconstitution calculator.

MOTS-c is one more peptide where the arithmetic trips people up more than the science. If you are reconstituting a vial, the reconstitution calculator converts mg, water, and syringe units for you, and the step-by-step reconstitution guide walks through the full process with a video. For the personal side of one MOTS-c run, the founder logs it on the blog. Tracking a protocol? The WeightSnap app records every injection and your vial supply natively.

WeightSnap is a tracking tool, not medical advice. This page is a technical reference about a research-chemical peptide. It does not recommend using MOTS-c, provides no dosing protocol, and should not replace guidance from a licensed healthcare provider. Regulatory details are accurate to the best of our knowledge as of July 2026 and are subject to change.